Trademark Overview
On Thursday, April 18, 2024, a trademark application was filed for DAASO with the United States Patent and Trademark Office. The USPTO has given the DAASO trademark a serial number of 98507858. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, November 12, 2024. This trademark is owned by Fosun Pharma USA Inc.. The DAASO trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical preparations for the treatment of central nervous system diseases, neuromuscular diseases, metabolic diseases, and diseases related to RNA processing and translation
Biochemical research and development; Biotechnology research; Gene therapy research; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Research and development in the field of RNA-targeted drugs; Research and development in the field of nucleic acids, biologics, central nervous system diseases, metabolic diseases, and small molecule drugs; Research and development in the field of gene therapy, namely, development of oligonucleotides that target more than one aspect of the RNA transcript splicing regulation machinery and process to enhance the potentiation or inhibition of that machinery and process; Research and development in the pharmaceutical and biotechnology fields; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy
